BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
BridgeBio Pharma (Nasdaq: BBIO) has announced the presentation of cardiovascular outcomes data from their ATTRibute-CM Phase 3 study of acoramidis in ATTR-CM at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, March 29-31, 2025.
The company will present seven studies, including five flatboard poster presentations and two moderated posters, focusing on various aspects of acoramidis treatment in ATTR-CM patients. Key presentations include:
- Acoramidis's impact on serum TTR levels in wild-type and variant ATTR-CM patients
- Improvements in NYHA Class at Month 30 versus placebo
- Effects of combining acoramidis with tafamidis
- Primary endpoint efficacy results and NT-proBNP sensitivity analyses
- Relationship between early serum transthyretin increase and reduced cardiovascular hospitalizations
- Geographic healthcare disparities in ATTR-CM diagnosis
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato la presentazione dei dati sugli esiti cardiovascolari del loro studio di fase 3 ATTRibute-CM su acoramidis in ATTR-CM durante il prossimo Collegio Americano di Cardiologia (ACC) Annual Scientific Sessions a Chicago, dal 29 al 31 marzo 2025.
La compagnia presenterà sette studi, inclusi cinque poster su flatboard e due poster moderati, concentrandosi su vari aspetti del trattamento con acoramidis nei pazienti con ATTR-CM. Le presentazioni chiave includono:
- L'impatto di acoramidis sui livelli sierici di TTR nei pazienti con ATTR-CM di tipo wild-type e variante
- Miglioramenti nella Classe NYHA al mese 30 rispetto al placebo
- Effetti della combinazione di acoramidis con tafamidis
- Risultati di efficacia del punto finale primario e analisi di sensibilità di NT-proBNP
- Relazione tra l'aumento precoce del transtiretina sierica e la riduzione delle ospedalizzazioni cardiovascolari
- Disparità geografiche nell'assistenza sanitaria nella diagnosi di ATTR-CM
BridgeBio Pharma (Nasdaq: BBIO) ha anunciado la presentación de datos sobre los resultados cardiovasculares de su estudio de fase 3 ATTRibute-CM de acoramidis en ATTR-CM en la próxima Sesión Científica Anual del Colegio Americano de Cardiología (ACC) en Chicago, del 29 al 31 de marzo de 2025.
La compañía presentará siete estudios, incluyendo cinco presentaciones en cartelera y dos carteles moderados, centrándose en varios aspectos del tratamiento con acoramidis en pacientes con ATTR-CM. Las presentaciones clave incluyen:
- El impacto de acoramidis en los niveles séricos de TTR en pacientes con ATTR-CM de tipo salvaje y variante
- Mejoras en la Clase NYHA al mes 30 en comparación con el placebo
- Efectos de combinar acoramidis con tafamidis
- Resultados de eficacia del punto final primario y análisis de sensibilidad de NT-proBNP
- Relación entre el aumento temprano de transtiretina sérica y la reducción de hospitalizaciones cardiovasculares
- Disparidades geográficas en el diagnóstico de ATTR-CM
BridgeBio Pharma (Nasdaq: BBIO)는 ATTR-CM에 대한 acoramidis의 ATTRibute-CM 3상 연구의 심혈관 결과 데이터를 발표한다고 발표했습니다. 발표는 2025년 3월 29일부터 31일까지 시카고에서 열리는 미국심장학회(ACC) 연례 과학 세션에서 진행됩니다.
회사는 ATTR-CM 환자에 대한 acoramidis 치료의 다양한 측면에 초점을 맞춘 다섯 개의 플랫보드 포스터 발표와 두 개의 조정된 포스터를 포함하여 총 일곱 개의 연구를 발표할 예정입니다. 주요 발표 내용은 다음과 같습니다:
- 야생형 및 변종 ATTR-CM 환자에서의 acoramidis가 혈청 TTR 수준에 미치는 영향
- 위약 대비 30개월 후 NYHA 클래스 개선
- acoramidis와 tafamidis의 병용 효과
- 주요 목표 효능 결과 및 NT-proBNP 민감도 분석
- 조기 혈청 트랜스티레틴 증가와 심혈관 입원 감소 간의 관계
- ATTR-CM 진단에서의 지리적 의료 불균형
BridgeBio Pharma (Nasdaq: BBIO) a annoncé la présentation de données sur les résultats cardiovasculaires de leur étude de phase 3 ATTRibute-CM sur acoramidis dans l'ATTR-CM lors des prochaines Sessions Scientifiques Annuelles du Collège Américain de Cardiologie (ACC) à Chicago, du 29 au 31 mars 2025.
L'entreprise présentera sept études, y compris cinq présentations de posters sur flatboard et deux posters modérés, se concentrant sur divers aspects du traitement par acoramidis chez les patients atteints d'ATTR-CM. Les présentations clés incluent :
- L'impact d'acoramidis sur les niveaux sériques de TTR chez les patients atteints d'ATTR-CM de type sauvage et variant
- Améliorations de la classe NYHA au mois 30 par rapport au placebo
- Effets de la combinaison d'acoramidis avec tafamidis
- Résultats d'efficacité du critère d'évaluation principal et analyses de sensibilité de NT-proBNP
- Relation entre l'augmentation précoce de la transthyretine sérique et la réduction des hospitalisations cardiovasculaires
- Disparités géographiques dans le diagnostic de l'ATTR-CM
BridgeBio Pharma (Nasdaq: BBIO) hat die Präsentation von kardiovaskulären Ergebnissen aus ihrer ATTRibute-CM Phase 3 Studie zu acoramidis in ATTR-CM bei den bevorstehenden Jahrestagungen der American College of Cardiology (ACC) in Chicago, vom 29. bis 31. März 2025, angekündigt.
Das Unternehmen wird sieben Studien präsentieren, darunter fünf Flatboard-Posterpräsentationen und zwei moderierte Poster, die sich auf verschiedene Aspekte der Behandlung mit acoramidis bei ATTR-CM-Patienten konzentrieren. Zu den wichtigsten Präsentationen gehören:
- Die Auswirkungen von acoramidis auf die Serum-TTR-Spiegel bei Wildtyp- und Varianten-ATTR-CM-Patienten
- Verbesserungen der NYHA-Klasse nach 30 Monaten im Vergleich zu Placebo
- Wirkungen der Kombination von acoramidis mit tafamidis
- Ergebnisse der primären Endpunkt-Effektivitätsanalyse und NT-proBNP-Sensitivitätsanalysen
- Zusammenhang zwischen frühem Anstieg der Serum-Transthyretin-Spiegel und reduzierten kardiovaskulären Krankenhausaufenthalten
- Geografische Ungleichheiten im Gesundheitswesen bei der Diagnose von ATTR-CM
- None.
- None.
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.
Flatboard Poster Presentations:
Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy
Presenter: Margot Davis, M.D. of Vancouver General Hospital, CA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET
Acoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study
Presenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET
In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR Levels
Presenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET
Robustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity Analyses
Presenter: Jan Griffin, M.D. of Medical University of South Carolina, USA
Date: Sunday, March 30 at 1:30 pm CT/2:30 pm ET
Acoramidis-mediated Early Increase in Serum Transthyretin Level Reduces Cardiovascular-related Hospitalizations and Mortality: Insights from the ATTRibute-CM Study
Presenter: Nitasha Sirwat, M.D. of UChicago Medicine, USA
Date: Monday, March 31 at 9:00 am CT/10:00 am ET
Moderated Posters:
Primary Endpoint Efficacy Results in the ATTRibute-CM Study: Pre-specified Sensitivity Analyses Addressed Tafamidis Use
Presenter: Daniel P. Judge, M.D. of Medical University of South Carolina, USA
Date: Saturday, March 29 at 10:06 am CT/11:06 am ET
Geographic Healthcare Disparities and Diagnostic Trends Among Patients with Transthyretin Amyloid Cardiomyopathy
Presenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USA
Date: Saturday, March 29 at 10:54 am CT/11:54 am CT
About Attruby™ (acoramidis)
Attruby is the first near-complete (≥
About BridgeBio
BridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
FAQ
What are the key findings of BridgeBio's (BBIO) ATTRibute-CM Phase 3 study being presented at ACC 2025?
When and where will BridgeBio (BBIO) present its ATTRibute-CM study results?
How many presentations will BridgeBio (BBIO) deliver at ACC 2025 regarding acoramidis?
What is the interaction between acoramidis and tafamidis in BBIO's ATTRibute-CM study?
How does acoramidis affect NYHA Class in ATTR-CM patients according to BBIO's study?
